Brief: Shenzhen Hepalink Pharmaceutical Sees FY Net Profit Attributable RMB589.00 Mln To RMB711.00 Mln
24/01/2025 10:39
Jan 24 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group Co Ltd 002399.SZ :
* SEES NET PROFIT ATTRIBUTABLE RMB589.00 MILLION TO
RMB711.00
MILLION FOR YEAR
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA